Harpoon Finds A Blood Cancer Partner In AbbVie
The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.
The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.